Duchenne muscular dystrophy (DMD)

duchenne muscular dystrophy
Biotech

FDA skips AdComm for Sarepta's DMD therapy, sets decision date

The FDA won’t be holding an advisory panel meeting for Sarepta’s SRP-9001, which could become the first gene therapy for Duchenne muscular dystrophy.
Gabrielle Masson Feb 28, 2023 8:00pm
European Medicines Agency

EMA gives support to Duchenne trial simulation platform

Jan 26, 2023 5:00am
FDA

Fresh from Vertex payday, Entrada's DMD plans derailed by FDA

Dec 20, 2022 8:45am
war chest treasure chest gold money cash box

Sarepta preps $1.2B war chest for DMD gene therapy

Nov 3, 2022 10:02am
Halloween line trick or treat costumes spooky queue

Santhera loses interest in pulmonary drug to focus on DMD

Oct 31, 2022 10:25am
stop light green

Sarepta, freed from phase 2 clinical hold, picks up momentum

Sep 6, 2022 11:28am